Dickinson Andrew D's Form 4 filing
Gilead Sciences, Inc. (GILD) · filed Jul 16, 2026
- Accession no.
- 0001310204-26-000022
- Filed
- Jul 16, 2026, 6:08 PM ET
- Trade date
- Jul 15, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $389.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dickinson Andrew DCIK 0001310204 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | SSaleDisposed | −3,000 | $129.93F2 | −$389,776.8 | 168,646 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.